VERNON HILLS, Ill., June 1, 2017 /PRNewswire/ --áNexus Pharmaceuticals announced today the immediate availability in the United States of Sodium Nitroprusside Injection. Nexus Pharmaceuticals' Sodium Nitroprusside Injection is available as a single dose vial containing 50 mg per 2mL (25mg/mL) and is an AP Rated generic equivalent of Nitropress«.
About Nexus Pharmaceuticals Inc.
Nexus Pharmaceuticals (www.nexuspharma.net) is a U.S. based healthcare company that specializes in developing and marketing generic sterile injectable products. Through our high quality generic products, Nexus Pharmaceuticals is committed to providing patients with affordable prescription medicines that lower healthcare costs and provide a better quality of life. The company's headquarters is in Vernon Hills, Illinois.
Nitropress« is a registered trademark of Hospira Inc.
Media ContactNexus Pharmaceuticals Inc. Ayesha Ahmed847email@example.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nexus-pharmaceuticals-receives-fda-approval-for-sodium-nitroprusside-injection-300467416.html
SOURCE Nexus Pharmaceuticals Inc.
Subscribe to our Free Newsletters!
Angiogenesis is the process of formation of new blood vessels from pre-existing blood vessels. It ...
Aniridia is a genetic eye disorder in which the iris is partially or entirely absent. It is ...
Cachexia refers to severe muscle and fat loss, anorexia and marked weight loss due to an underlying ...View All